MX2017009406A - Compuestos de tipo isoergolina y usos de estos. - Google Patents

Compuestos de tipo isoergolina y usos de estos.

Info

Publication number
MX2017009406A
MX2017009406A MX2017009406A MX2017009406A MX2017009406A MX 2017009406 A MX2017009406 A MX 2017009406A MX 2017009406 A MX2017009406 A MX 2017009406A MX 2017009406 A MX2017009406 A MX 2017009406A MX 2017009406 A MX2017009406 A MX 2017009406A
Authority
MX
Mexico
Prior art keywords
compounds
pharmaceutical compositions
methods
compositions disclosed
still
Prior art date
Application number
MX2017009406A
Other languages
English (en)
Inventor
ARMER Thomas
Mckinley Geoff
Borland Scott
Guzman Miguel
Original Assignee
Xoc Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoc Pharmaceuticals Inc filed Critical Xoc Pharmaceuticals Inc
Publication of MX2017009406A publication Critical patent/MX2017009406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se proporcionan compuestos de tipo isoergolina y composiciones farmacéuticas de estos. En otras realizaciones, en la presente se proporcionan métodos de tratamiento, prevención y mejora de varios trastornos médicos tales como, por ejemplo, la migraña utilizando los compuestos y composiciones farmacéuticas divulgados en la presente. En otras realizaciones más, en la presente se proporcionan métodos para ejercer un efecto agonista sobre receptores tales como, por ejemplo, los receptores 5-1-1111A, 5-HT1B Y 5-HT1D sin ejercer un efecto agonista sobre el receptor 5-HTB utilizando los compuestos y composiciones farmacéuticas que se divulgan en la presente. En otras realizaciones más, en la presente se proporcionan métodos para ejercer un efecto antagonista sobre los receptores 5-HT2 alfa2A yio alfan adrenérgicos utilizando los compuestos y composiciones farmacéuticas divulgados en la presente. En otras realizaciones más, en la presente se proporcionan métodos para ejercer un efecto antagonista sobre los receptores 02 y D3 utilizando los compuestos y composiciones farmacéuticas divulgados en la presente.
MX2017009406A 2015-01-20 2016-01-20 Compuestos de tipo isoergolina y usos de estos. MX2017009406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105207P 2015-01-20 2015-01-20
PCT/US2016/013978 WO2016118539A2 (en) 2015-01-20 2016-01-20 Isoergoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2017009406A true MX2017009406A (es) 2018-01-18

Family

ID=56407316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009406A MX2017009406A (es) 2015-01-20 2016-01-20 Compuestos de tipo isoergolina y usos de estos.

Country Status (10)

Country Link
US (3) US9676776B2 (es)
EP (1) EP3247357A4 (es)
JP (1) JP2018502889A (es)
CN (1) CN107405346A (es)
AU (1) AU2016209490B2 (es)
BR (1) BR112017015510A2 (es)
CA (1) CA2974113A1 (es)
IL (1) IL253459B (es)
MX (1) MX2017009406A (es)
WO (1) WO2016118539A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA470573A (en) 1951-01-02 Stoll Arthur Sympatheticolytically active dihydro-derivatives of lysergic acid amides and their manufacture
US2086559A (en) 1936-01-30 1937-07-13 Lilly Co Eli Hydrogenated ergotocin
DE1770227A1 (de) 1967-04-20 1972-03-30 Richter Gedeon Vegyeszet Lysergsaeureamide und Verfahren zu deren Herstellung
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
SE396753B (sv) 1970-05-18 1977-10-03 Richter Gedeon Vegyeszet Analogiforfarande for framstellning av en forening tillhorande dihydrolysergsyraserien
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3922347A (en) 1974-12-19 1975-11-25 Lilly Co Eli Method of inhibiting prolactin secretion with 8-acylaminoergolenes
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CH644606A5 (de) 1980-09-23 1984-08-15 Sandoz Ag Verfahren zur isomerisierung von 9,10-dihydrolysergsaeurederivaten.
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
FI76085C (fi) 1981-07-21 1988-09-09 Erba Farmitalia Foerfarande foer framstaellning av ergolinderivat.
DE3135305C2 (de) * 1981-09-03 1983-07-21 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 8-Ergolinyl-harnstoffen
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
CS231214B1 (en) 1982-03-12 1984-10-15 Antonin Cerny Processing method of 1-substituted n+l8alpha-ergoline+p-n,diethyl urea
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3340025C2 (de) * 1983-11-03 1986-01-09 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 2-Brom-8-ergolinyl-Verbindungen
NL193541C (nl) * 1984-01-12 2000-01-04 Novartis Ag 8 Alfa-acylaminoergolinen, werkwijzen voor de bereiding daarvan en preparaten die ze bevatten.
DE3587860D1 (de) * 1984-04-09 1994-07-28 Schering Ag 2-substituierte Ergolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE3413660A1 (de) * 1984-04-09 1985-10-17 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 2-(trialkyl-silyl)-ergolinderivaten
DE3413657A1 (de) * 1984-04-09 1985-10-17 Schering AG, 1000 Berlin und 4709 Bergkamen Neue ergoline
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4679462A (en) 1984-12-24 1987-07-14 Sundstrand Corporation Differential transmission mechanism for a constant speed drive
EP0208417A3 (en) 1985-06-12 1989-09-06 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis
NL8700046A (nl) * 1986-01-24 1987-08-17 Sandoz Ag 8 alfa-acylaminoergolinen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
DE3623503A1 (de) * 1986-07-09 1988-01-21 Schering Ag 1-aryl-ergolinyl-harnstoffderivate, verfahren zu deren herstellung sowie die verwendung dieser verbindungen als arzneimittel
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US4828950A (en) 1987-12-28 1989-05-09 Eastman Kodak Company Method for making multi-color reproductions on plain bond paper
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE3915950A1 (de) 1989-05-12 1990-11-15 Schering Ag 8(alpha)-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
DE3931819A1 (de) 1989-09-20 1991-03-28 Schering Ag 13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DE4123587A1 (de) * 1991-07-12 1993-01-14 Schering Ag 2,14-disubstituierte ergoline, deren herstellung und verwendung in arzneimitteln
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
WO1997004629A1 (en) 1995-07-14 1997-02-06 Olin Corporation Metal ball grid electronic package
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
AU3408097A (en) 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US6221070B1 (en) 1996-10-18 2001-04-24 Irvine Biomedical, Inc. Steerable ablation catheter system having disposable shaft
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
GB9711043D0 (en) 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
AU2002305845B2 (en) 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
WO2003013611A1 (fr) * 2001-08-10 2003-02-20 Hisamitsu Pharmaceutical Co., Inc. Preparations a absorption par voie cutanee
DE10249401A1 (de) 2002-10-23 2004-05-13 Bernina Biosystems Gmbh Liposomen formende Zusammensetzung
KR100795425B1 (ko) 2003-04-11 2008-01-17 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 소마토스타틴-도파민 키메라 유사체
EP1663159A4 (en) 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US7650848B2 (en) 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
US20100168119A1 (en) 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
WO2010065930A1 (en) 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CA3034600C (en) 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
US20140058108A1 (en) * 2010-11-11 2014-02-27 Sinoxa Pharma Ug Lisuride, Terguride and Derivatives Thereof for Use in the Prophylaxis and/or Treatment of Fibrotic Changes
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
EP2793580A4 (en) * 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
AU2012355983A1 (en) * 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN105189492A (zh) 2012-11-19 2015-12-23 萨克·W·金 麦角灵衍生物作为多巴胺受体调节剂
US20140179705A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
JP2016503796A (ja) 2012-12-21 2016-02-08 マップ ファーマシューティカルズ インコーポレイテッド フルオロエルゴリン誘導体およびその使用
EP2935280A4 (en) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2014100359A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel ergoline derivatives and uses thereof
WO2014186623A2 (en) 2013-05-17 2014-11-20 Biomed Valley Discoveries Methods and compositions for the treatment of a chagas disease
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc エルゴリン化合物およびその使用

Also Published As

Publication number Publication date
CA2974113A1 (en) 2016-07-28
JP2018502889A (ja) 2018-02-01
WO2016118539A3 (en) 2016-11-24
US9815830B2 (en) 2017-11-14
CN107405346A (zh) 2017-11-28
US20170233387A1 (en) 2017-08-17
EP3247357A4 (en) 2018-07-11
US20170233404A1 (en) 2017-08-17
US9676776B2 (en) 2017-06-13
US20160207920A1 (en) 2016-07-21
AU2016209490B2 (en) 2020-09-03
BR112017015510A2 (pt) 2018-01-30
US9777016B2 (en) 2017-10-03
WO2016118539A2 (en) 2016-07-28
IL253459A0 (en) 2017-09-28
EP3247357A2 (en) 2017-11-29
AU2016209490A1 (en) 2017-08-31
IL253459B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2017009405A (es) Compuestos de tipo ergolina y usos de estos.
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MY191581A (en) Anti-pd-1 antibodies
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
EP3536168A3 (en) Probiotic formulations and methods for use
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
SG10201803042PA (en) Anti-tim-3 antibodies
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP4663247A3 (en) Formulations/compositions comprising a btk inhibitor
WO2015001541A3 (en) Pharmaceutical film composition
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
BR112015014957A2 (pt) derivados de fluoroergolina e usos dos mesmos
EP4480577A3 (en) Structured elements and methods of use
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
WO2017087917A3 (en) Bicarbonate biosensors, calcium biosensors, and uses thereof
HK1249756A1 (zh) 用於治疗疾病的稠合双环化合物
WO2016118539A3 (en) Isoergoline compounds and uses thereof
IL251249B (en) Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease